Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer

13 november 2019 uppdaterad av: University of Wisconsin, Madison

Mindfulness-Based Interventions in Patients Treated for Gynecologic Cancer - Impact on Patient Reported Outcomes and Immunologic Correlates

This pilot clinical trial studies how well a mindfulness-based stress reduction (MBSR) intervention works in reducing anxiety in patients who have undergone treatment for gynecologic cancer but no longer have any sign of disease. Gynecologic cancer is cancer of the female reproductive tract, which includes the cervix, endometrium, fallopian tubes, ovaries, uterus, and vagina. Side effects from treatment for these cancers may include anxiety, fatigue, depression, and sexual function changes. Mindfulness training uses meditation and yoga to help patients focus on breathing, bodily sensations, and mental awareness. This may help decrease patients' stress and anxiety and improve their quality of life, and may also help their immune system.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Patients are randomized to 1 of 2 Arms.

ARM I (INTERVENTION): Patients undergo an 8-week MBSR course, comprising weekly 2.5 hour classes and one 6-hour Saturday class at week 6 or 7. The MBSR program involves instruction in mindfulness meditation and yoga, and gives homework assignments involving practicing the well-being techniques taught in class. Patients are required to record and report time spent on home practice in a journal daily, and receive a weekly reminder to report their home practice.

ARM II (WAIT-LIST CONTROL): Patients do not participate in the intervention, but are given the option to be placed on a waitlist for the MBSR course and may complete it within 6 months after the final study visit.

After completion of study, patients are followed up at 8 weeks (at completion of study) and 5 months (3 months from study completion).

Studietyp

Interventionell

Inskrivning (Faktisk)

38

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • Wisconsin
      • Madison, Wisconsin, Förenta staterna, 53705
        • University of Wisconsin Carbone Cancer Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Diagnosis of any invasive gynecologic cancer without evidence of disease.
  • Gynecologic cancer treatment (e.g., surgery, chemotherapy, radiation therapy) was completed within 5 years prior to date of enrollment.
  • Able to speak, read and write English
  • ECOG Performance Status between 0 and 3
  • Subjects must have a phone.
  • Experiencing 2 or more of the following symptoms felt to be associated (per the patient) with gynecologic cancer or previous gynecologic cancer treatment: anxiety (worry or feeling stressed), cognitive impairment (difficulty concentrating, focusing, memory loss), depression, existential/spiritual distress (hopelessness, lack of meaning in life, lack of peace), fatigue, pain, and sexual dysfunction. These symptoms may be new or worsened since cancer diagnosis. Both symptoms fomr this list must have been present one week prior to eligibility assessment, with worst severity rating greater than or equal to 3 (0-10 scale) for at least 1 of the 2 symptoms
  • Expected to continue cancer care at UWCCC for the duration of the study.

Exclusion Criteria:

  • Undergone cancer treatment (excluding hormonal therapy or biological maintenance therapy) in the 4 weeks prior to enrollment
  • Expected to require cancer treatment, other than biologic or hormonal maintenance therapy, during the course of the study
  • Any other cancer present within the last 5 years (other than gynecologic cancer under study and non-melanoma skin cancer)
  • Practicing mindfulness meditation for an average of more than 1 hour/week or have taken mindfulness training in the past
  • Documented history of Alzheimer's disease, dementia, or other neurologic deficit that could impact decision-making
  • Prisoner or incarcerated

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Stödjande vård
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Arm I (MBSR intervention)
Patients undergo an 8-week MBSR course, comprising weekly 2.5 hour classes and one 6-hour Saturday class at week 6 or 7. The MBSR program involves instruction in mindfulness meditation and yoga, and gives homework assignments involving practicing the well-being techniques taught in class. Patients are required to record and report time spent on home practice in a journal daily, and receive a weekly reminder to report their home practice.
Beteende: Mindfulness-Based Stress Reduction
The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
Andra namn:
  • MBSR
Inget ingripande: Arm II (control)
Patients do not participate in the intervention, but are given the option to be placed on a waitlist for the MBSR course and may complete it within 6 months after the final study visit.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in anxiety
Tidsram: Baseline to up to 5 months
Measured by the 8-item anxiety subscale of the PROMIS scale.
Baseline to up to 5 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in depression
Tidsram: Baseline to up to 5 months
Measured by PROMIS subscale for depression.
Baseline to up to 5 months
Change in fatigue
Tidsram: Baseline to up to 5 months
Measured by PROMIS subscale for fatigue.
Baseline to up to 5 months
Change in sleep disturbance
Tidsram: Baseline to up to 5 months
Measured by PROMIS subscale for sleep disturbance.
Baseline to up to 5 months
Change in sexual function
Tidsram: Baseline to up to 5 months
Measured by Female Sexual Function Profile and Global Satisfaction with Sex Life questionnaire.
Baseline to up to 5 months
Change in existential/spiritual distress
Tidsram: Baseline to up to 5 months
measured by Functional Assessment of Chronic Illness Therapy - Spiritual Well-Being Scale (FACIT-SP-12 version 4)
Baseline to up to 5 months
Change in cognitive function
Tidsram: Baseline to up to 5 months
Measured by the NIH Toolbox Assessments
Baseline to up to 5 months
Change in cortisol levels
Tidsram: Baseline to up to 5 months
The biobehavioral link between MBSR intervention-related Quality of Life changes and immune cell function will be explored.
Baseline to up to 5 months
Change in levels of pro-inflammatory cytokines
Tidsram: Baseline to up to 5 months
The biobehavioral link between MBSR intervention-related Quality of Life changes and immune cell function will be explored.
Baseline to up to 5 months
Change in immune cell phenotypes
Tidsram: Baseline to up to 5 months
The biobehavioral link between MBSR intervention-related Quality of Life changes and immune cell function will be explored.
Baseline to up to 5 months
Change in NK cell function
Tidsram: Baseline to up to 5 months
The biobehavioral link between MBSR intervention-related Quality of Life changes and immune cell function will be explored.
Baseline to up to 5 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

University of Wisconsin, Madison

Utredare

  • Huvudutredare: Ryan Spencer, University of Wisconsin, Madison

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Användbara länkar

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

18 november 2015

Primärt slutförande (Faktisk)

20 juni 2019

Avslutad studie (Faktisk)

20 juni 2019

Studieregistreringsdatum

Först inskickad

4 augusti 2015

Först inskickad som uppfyllde QC-kriterierna

4 augusti 2015

Första postat (Uppskatta)

7 augusti 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 november 2019

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

13 november 2019

Senast verifierad

1 juli 2019

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • UW15000
  • A532820 (Annan identifierare: UW Madison)
  • 2015-0549 (Annan identifierare: Institutional Review Board)
  • SMPH\OBSTET & GYNECOL\OB-GYN (Annan identifierare: UW Madison)
  • NCI-2015-01263 (Registeridentifierare: NCI Trial ID)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera